FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma

December 23, 2019 – The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma. Currently, the agent is being evaluated in an ongoing, open-label, nonrandomized phase I trial (NCT03600649) in patients with Ewing sarcoma. In the study, researchers are aiming to find an optimal dose of SP-2577 using an accelerated dose-escalation followed … (leggi tutto)